o-Tolunitrile, also known as 2-methylbenzonitrile, is an organic compound with the formula CH3C6H4CN. It is a colorless liquid with a characteristic aromatic odor. o-Tolunitrile is primarily used as an intermediate in the synthesis of other chemicals, including pharmaceuticals, dyes, and pesticides. It is also a valuable building block in the production of polymers and resins. The compound is synthesized through various methods, including the dehydration of o-toluamide, the reaction of o-toluenesulfonyl chloride with cyanide, and the Friedel-Crafts acylation of toluene with cyanogen chloride. o-Tolunitrile has been studied for its potential applications in various fields, such as its use as a solvent in organic reactions, its ability to inhibit corrosion, and its role in the development of novel materials. The compound has also been investigated for its biological activity, showing potential as an antimicrobial agent.'
o-tolunitrile: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10721 |
| CHEMBL ID | 1361840 |
| SCHEMBL ID | 74392 |
| MeSH ID | M0542914 |
| Synonym |
|---|
| AC-3136 |
| 2-methyl-benzonitrile |
| o-cyanotoluene |
| wln: ncr b1 |
| o-methylbenzonitrile |
| nsc66549 |
| o-tolunitrile |
| 1-methyl-2-cyanobenzene |
| o-toluic nitrile |
| o-toluonitrile |
| 2-methylbenzenecarbonitrile |
| nsc-66549 |
| 2-cyanotoluene |
| o-tolylnitrile |
| 2-methylbenzonitrile |
| inchi=1/c8h7n/c1-7-4-2-3-5-8(7)6-9/h2-5h,1h |
| 529-19-1 |
| benzonitrile, 2-methyl- |
| NCGC00091316-01 |
| 2-toluenkarbonitril [czech] |
| ai3-17128 |
| ccris 1286 |
| nsc 66549 |
| einecs 208-451-7 |
| o-tolunitrile, >=97.0% (gc) |
| MLS002415767 |
| smr001370922 |
| FT-0651216 |
| T0306 |
| AKOS000120443 |
| NCGC00091316-02 |
| HMS3039P17 |
| NCGC00257878-01 |
| 2-tolunitrile |
| cas-529-19-1 |
| dtxcid702050 |
| dtxsid6022050 , |
| tox21_200324 |
| A829308 |
| STL168510 |
| benzonitrile, methyl- |
| 25550-22-5 |
| methylbenzonitrile |
| 2-toluenkarbonitril |
| 3048f2a3kt , |
| unii-3048f2a3kt |
| tolunitrile, o- |
| o-tolunitrile [mi] |
| SCHEMBL74392 |
| tolunitrile |
| toluonitrile |
| orthotolunitrile |
| ortho-tolunitrile |
| CHEMBL1361840 |
| 1-cyano-2-methylbenzene |
| mfcd00001792 |
| F0001-1362 |
| o-tolunitril |
| Q22830837 |
| AMY40128 |
| o-tolyl cyanide |
| 1138681-69-2 |
| AS-56478 |
| EN300-20470 |
| o-tolunitrile-d7 |
| Z104478334 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 9.7331 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 12.5893 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 61.2296 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| geminin | Homo sapiens (human) | Potency | 10.3225 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 12.5893 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| double-stranded DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| RNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mRNA 3'-UTR binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| lipid binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| identical protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| pre-mRNA intronic binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| molecular condensate scaffold activity | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| intracellular non-membrane-bounded organelle | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleus | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
| perichromatin fibrils | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mitochondrion | TAR DNA-binding protein 43 | Homo sapiens (human) |
| cytoplasmic stress granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nuclear speck | TAR DNA-binding protein 43 | Homo sapiens (human) |
| interchromatin granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
| chromatin | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.30) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||